Searchable abstracts of presentations at key conferences on calcified tissues

ba0006oc24 | (1) | ICCBH2017

KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH)

Imel Erik , Carpenter Thomas , Gottesman Gary S , Martin Javier San , Mao Meng , Skrinar Alison , Whyte Michael P

Objectives: XLH features renal phosphate (Pi) wasting, hypophosphatemia, rickets, and skeletal deformities from elevated circulating levels of fibroblast growth factor 23 (FGF23). KRN23, an investigational fully human monoclonal antibody, binds FGF23 and inhibits its action. Our Phase 2 study of KRN23 in XLH children (ages 5–12 years) is demonstrating improvements in serum Pi and rickets. Here we present our Phase 2 trial evaluating the efficacy and safety of KRN23 in you...

ba0003pp159 | Cell biology: osteoclasts and bone resorption | ECTS2014

Arachidonic acid and docosahexaenoic acid inhibits osteoclastogenesis and bone resorption in human CD14+ monocytes, in vitro

Kasonga Abe , Kruger Marlena , Coetzee Magdalena

The mature human skeleton is a metabolically active organ that is continuously resorbed and rebuilt by osteoclasts and osteoblasts. Dietary supplementation of selected long chain polyunsaturated fatty acids (LCPUFAs) has shown effects on bone turnover. Most research on LCPUFAs has been done using commercially available cell lines and further clarification of the cellular effects on models relevant to humans is required. After ethical approval, peripheral blood was collected fr...

ba0006p081 | (1) | ICCBH2017

Bone age determination using dual-energy X-ray absorptiometry

Alshamrani Khalaf , Offiah Amaka , kruger Elzene

Objective: To assess whether hand-wrist dual-energy x-ray absorptiometry (DXA) can replace radiographs for bone age assessment using the Greulich & Pyle (G&P) and/or Tanner & Whitehouse (TW3) methods.Methodology: Purposive sampling was used to include a total of 20 patients identified from an Endocrine Clinic; two males and two females from each of 5 age groups (<5; 5 to 7; 8 to 10; 11 to 13; 14 to 16 years). Bone age as determined from D...

ba0001pp128 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Mass spectrometric immunoassay for intact parathyroid hormone: correlation with immunoassay and application to clinical samples

Couchman L , Taylor D , Krystans B , Lopez M , Prakash A , Sarracino D , Garces A , Vogelsang M , Peterman S , Vadali G , Robinson S , Moniz C

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...

ba0001oc5.4 | Treatment of osteoporosis | ECTS2013

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

Graeff C , Campbell G , Pena J , Padhi D , Grossman A , Chang S , Libanati C , Gluer C-C

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...